Publications by authors named "Miguel A Allo"
Article Synopsis
- - Despite the global impact of hypertension, treatment remains inadequate, leading to the development of new antihypertensive medications with unique action mechanisms.
- - This review highlights recent advancements in drug development, emphasizing innovations in drug formulations and the potential of modifying intestinal microbiota for better blood pressure management.
- - New agents like sacubitril/valsartan and SGLT2 inhibitors show promise as first-line treatments, while strategies involving prebiotics and probiotics may help in preventing hypertension and improving blood pressure control.
The accumulation of Ca and its subsequent increase in oxidative stress is proposed to be involved in selective dysfunctionality of dopaminergic neurons, the main cell type affected in Parkinson's disease. To test the in vivo impact of Ca increment in dopaminergic neurons physiology, we downregulated the plasma membrane Ca ATPase (PMCA), a pump that extrudes cytosolic Ca , by expressing PMCA in Drosophila melanogaster dopaminergic neurons. In these animals, we observed major locomotor alterations paralleled to higher cytosolic Ca and increased levels of oxidative stress in mitochondria.
View Article and Find Full Text PDFArticle Synopsis
- β-Adrenergic blockers are no longer first-line therapy for hypertension due to their reduced effectiveness compared to other medications.
- This study compared nebivolol and atenolol in hypertensive rats, revealing that nebivolol more effectively reduces both central systolic blood pressure and variability.
- Nebivolol also showed greater protection against target organ damage by decreasing inflammation and collagen deposition compared to atenolol, suggesting third-generation β-blockers may offer better cardioprotection.
Background: β-blockers are no longer considered as first-line antihypertensive drugs due to their lower cardioprotection.
Method: Considering the differences in the pharmacological properties of β-blockers, the present work compared the effects of third-generation β-blockers - carvedilol and nebivolol - with a first-line agent - amlodipine - on hemodynamic parameters, including short-term blood pressure variability (BPV), and their ability to prevent target organ damage in spontaneously hypertensive rats (SHR). SHR rats were orally treated with carvedilol, nebivolol, atenolol, amlodipine or vehicle for 8 weeks.